Transdermal drug delivery has a promising market which generates big revenue as \n \nwell give better clinical outcomes by avoiding first pass elimination through oral \n \nadministration and also painful experience through hypodermic injection. Due to skin \n \nnatural properties as the first barrier to bacterial infection and prevent dehydration, \n \ndrugs formulation in curing disease through transdermal patch is limited. Drug \n \nformulation for traditional Transdermal Delivery System has low molecular weight, \n \nless than 500 Da and high in hydrophobicity. Up to date, less than forty drug \n \nformulations were approved and commercially sold in the market. With the rapid \n \nadvancement in medical field, more complex drug formulations available nowadays \n \nto deal with various diseases have relatively larger molecular weight which in turns \n \nlimits the use of traditional transdermal patch as drugs administration route. After a \n \nfew decades focus on transdermal drug delivery system (TDDS), 2nd generation with \n \npenetration enhancer was used by patient now and dense researches carried out all \n \nover the world to have 3rd generation with less clinical complications, more \n \nconvenient for home use, and also cost efficient for mass vaccination campaigns in \n \ndeveloping countries. Microneedle is one of the candidates that can physically alter \n \nskin’s properties to allow macromolecules to pass through. This project focused on \n \nfinding the optimal protocol in fabricating biodegradable polymer microneedle and \n \nalso add-on function to actively control drug release profile.